Patents Assigned to Pierre Fabre Medicament
  • Patent number: 11173131
    Abstract: The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: November 16, 2021
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Isabel Ribeiro Dos Santos, Michel Sournac
  • Publication number: 20210338646
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Application
    Filed: June 25, 2021
    Publication date: November 4, 2021
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Bruno PAILLARD, Laurence DEL FRARI, Valérie BRUNNER, Adrian NEWMAN TANCREDI, Mark VARNEY
  • Patent number: 11090298
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: August 17, 2021
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
  • Publication number: 20210107868
    Abstract: The present invention concerns a compound of following formula (I): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ?a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ?—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ?an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ?a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
    Type: Application
    Filed: October 27, 2020
    Publication date: April 15, 2021
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Michel PEREZ, Ian Rilatt, Marie Lamothe
  • Publication number: 20210087278
    Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
    Type: Application
    Filed: March 16, 2020
    Publication date: March 25, 2021
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Liliane GOETSCH, Thierry WURCH, Cédric BES
  • Publication number: 20210038738
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: October 28, 2020
    Publication date: February 11, 2021
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Marie Lamothe
  • Patent number: 10912841
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 9, 2021
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Ian Rilatt, Michel Perez, Marie Lamothe
  • Patent number: 10881702
    Abstract: The invention relates to a compound selected from among celastrol, the derivatives thereof and the pharmaceutically acceptable salts of celastrol and its derivatives, or a composition comprising such a compound for use in the topical prevention and/or treatment of a tumour or precancerous disease of the skin.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: January 5, 2021
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Thien Nguyen, Arnaud Pillon
  • Publication number: 20200383976
    Abstract: The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 10, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Françoise TONNER, Armida MUCCI
  • Patent number: 10858423
    Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 8, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Alexandra Jouhanneaud, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert, Jean-François Haeuw, Ian Rilatt, Michel Perez, Marie Lamothe
  • Patent number: 10842789
    Abstract: The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 24, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Françoise Tonner, Armida Mucci
  • Publication number: 20200308242
    Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.
    Type: Application
    Filed: April 1, 2020
    Publication date: October 1, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Peter LOWE, Jean-François HAEUW, Alicia CONTET, Céline BERTAUX, Barbara AKLA, Marie-Claire JANIN-BUSSAT
  • Patent number: 10766959
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 8, 2020
    Assignee: Pierre Fabre Medicament
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Publication number: 20200270352
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 27, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT, Marie LAMOTHE
  • Patent number: 10753937
    Abstract: The present disclosure relates to IGF-IR (insulin like growth factor receptor-1) antibodies characterized by CDR sequences a, to be used in detection methods of IGF-IR expressing tumoral cells.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: August 25, 2020
    Assignee: Pierre Fabre Medicament
    Inventor: Alexandra Jouhanneaud
  • Publication number: 20200138800
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Application
    Filed: December 17, 2019
    Publication date: May 7, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Bruno PAILLARD, Laurence DEL FRARI, Valérie BRUNNER, Adrian NEWMAN TANCREDI, Mark VARNEY
  • Publication number: 20200138888
    Abstract: The invention relates to a compound selected from among celastrol, the derivatives thereof and the pharmaceutically acceptable salts of celastrol and its derivatives, or a composition comprising such a compound for use in the topical prevention and/or treatment of a tumour or precancerous disease of the skin.
    Type: Application
    Filed: February 17, 2017
    Publication date: May 7, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Thien NGUYEN, Arnaud PILLON
  • Patent number: 10633448
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: April 28, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
  • Publication number: 20200093879
    Abstract: The invention relates to a use of Copaifera oleoresin for producing a medicament for preventing and/or treating pathologies of the prostate, particularly benign prostatic hyperplasia and/or prostate cancer.
    Type: Application
    Filed: March 20, 2018
    Publication date: March 26, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventor: Christel FIORINI-PUYBARET
  • Publication number: 20200040102
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: July 23, 2019
    Publication date: February 6, 2020
    Applicant: Pierre Fabre Medicament
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA